Quantitative Platelet Disorders

EDTA-dependent platelet clumping and platelet satellitosis, in which platelets form rosettes around neutrophils, falsely lower the automated count. Clumps counted as white-cell-sized particles can also raise the WBC count, producing pseudoleukocytosis. Room-temperature-reactive platelet autoantibodies contribute to both phenomena. The blood film detects both before an incorrect result is reported, so review the film whenever the count and the film disagree.^{11 Keohane EM, et al. Rodak's Hematology. 2025.}

Congenital causes. Most inherited thrombocytopenias map to specific genes, and estimating platelet size on the film is the fastest way to narrow the differential.^{11 Keohane EM, et al. Rodak's Hematology. 2025.}

Immune thrombocytopenia

Current terminology defines immune thrombocytopenia (ITP) by duration: newly diagnosed under 3 months, persistent from 3 to 12 months, and chronic beyond 12 months.^{66 Rodeghiero F, et al. Standardization of terminology, definitions and outcome criteria… 2009.}

ITP remains a diagnosis of exclusion. Neither the count, platelet size, age, nor a preceding infection confirms it. Review the CBC and film for other cytopenias, abnormal cells, fragmentation, and clumping, and assess possible secondary causes. The autoimmune process can both accelerate platelet destruction and impair production. The course varies at every age. Remission is more common in children, and onset can be abrupt or gradual at any age.^{22 Neunert C, et al. American Society of Hematology 2019 guidelines for immune… 2019.}

Immunologic drug-induced thrombocytopenia

Several mechanisms can cause drug-induced immune thrombocytopenia, and only some of them are drug-dependent:

Heparin-induced thrombocytopenia (HIT) is the laboratory-urgent member of this group. In the 4Ts score, the highest-scoring pattern is a platelet count fall greater than 50% with a nadir of at least 20 × 10³/µL and a clear onset 5 to 10 days after heparin exposure.^{77 Cuker A, et al. Predictive value of the 4Ts scoring system for heparin-induced… 2012.} The main risk is thrombosis. The 4Ts score weighs thrombocytopenia depth, timing, thrombosis, and competing causes to set the pretest probability. Heparin-platelet factor 4 immunoassays are used for screening, and functional assays such as the serotonin-release assay are used for confirmation. When a heparin-exposed patient develops a new thrombocytopenia, flag it promptly, because the risk of thrombosis begins at the same time. The clinical and transfusion services determine anticoagulation and transfusion support.^{88 Cuker A, et al. American Society of Hematology 2018 guidelines for management of… 2018.}

Thrombotic microangiopathies

Thrombotic microangiopathy (TMA) combines thrombocytopenia, arteriolar and capillary microthrombi, and microangiopathic hemolytic anemia. The pattern also appears with drugs such as clopidogrel and ticlopidine, transplantation, malignancy, pregnancy, disseminated intravascular coagulation (DIC), catastrophic antiphospholipid syndrome, autoimmune disease, HIV, and malignant hypertension.

Thrombotic thrombocytopenic purpura (TTP). Severe ADAMTS13 deficiency permits ultralarge VWF multimers to sustain platelet-rich microthrombi. TTP may be immune-mediated or congenital. Thrombocytopenia with microangiopathic hemolytic anemia calls for urgent notification even without the classic five clinical findings. Schistocytes, increased lactate dehydrogenase (LDH) and indirect bilirubin, and decreased haptoglobin support the hemolytic pattern. Organ involvement overlaps with other TMAs.^{99 Zheng XL, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic… 2020.}

The prothrombin time (PT) and activated partial thromboplastin time (APTT) are often less disturbed than in overt DIC. Coagulation results cannot reliably distinguish TTP from DIC. ADAMTS13 activity below 10% is the hallmark of TTP. Inhibitor or anti-ADAMTS13 antibody testing helps establish the immune mechanism. Collect the ADAMTS13 specimen before plasma exchange or plasma-containing products when feasible, and communicate the urgent pattern promptly.^{99 Zheng XL, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic… 2020.}

The PLASMIC score estimates the probability of severe ADAMTS13 deficiency while testing is pending. It gives one point each for platelets below 30 × 10³/µL; evidence of hemolysis (reticulocytes above 2.5%, undetectable haptoglobin, or indirect bilirubin above 2 mg/dL); no active cancer in the preceding year; no solid-organ or stem-cell transplant; mean cell volume (MCV) below 90 fL; international normalized ratio (INR) below 1.5; and creatinine below 2 mg/dL. A high score supports suspicion of severe ADAMTS13 deficiency. Confirmation depends on the ADAMTS13 result. The score was developed for adults and is less reliable in children and patients with major comorbidities, including pregnancy, cancer, sepsis, or transplantation.^{9,109 Zheng XL, et al. ISTH guidelines for the diagnosis of thrombotic thrombocytopenic… 2020.10 Bendapudi PK, et al. Derivation and external validation of the PLASMIC score for… 2017.}

The laboratory communicates the urgent pattern, and the clinical and transfusion services then decide transfusion support in suspected TTP.

Hemolytic uremic syndrome (HUS). Shiga-toxin-associated HUS follows Shigella dysenteriae or enterohemorrhagic E. coli, especially O157:H7, with bloody diarrhea preceding the triad of hemolytic anemia, renal failure, and mild-to-moderate thrombocytopenia. Shiga toxin damages glomerular endothelium, and urinary findings include red cells, protein, and casts. Complement-mediated HUS often involves complement-regulatory protein variants, and secondary forms follow drugs, transplantation, malignancy, pregnancy, and severe hypertension. Prominent kidney injury favors HUS. Neurologic findings and the degree of fragmentation cannot reliably separate it from TTP at presentation. Report the TMA pattern urgently, and state in the report that TTP remains possible until the ADAMTS13 result is available.^{11 Keohane EM, et al. Rodak's Hematology. 2025.}

Disseminated intravascular coagulation (DIC). Coagulation activation consumes platelets in intravascular fibrin clots and consumes factors V, VIII, and fibrinogen. Acute DIC produces severe thrombocytopenia, prolonged clotting times, low fibrinogen, and a positive D-dimer. Chronic DIC leaves factors near normal with a moderately low platelet count and increased D-dimer or fibrin degradation products, and it can convert to the acute form. The ISTH overt-DIC score combines the platelet count, D-dimer, PT prolongation, and fibrinogen into a single laboratory decision rule for overt DIC. Interpret the score with its trend and the full clinical context.^{1111 Toh CH, et al. The scoring system of the Scientific and Standardisation… 2007.}

Purpura fulminans. Large, irregular, blue-black hemorrhages progress to tissue necrosis. The laboratory findings resemble DIC, with prolonged clotting times, thrombocytopenia, and hypofibrinogenemia. In neonates it suggests severe congenital protein C or S deficiency. In older children and adults, severe sepsis, especially from Neisseria meningitidis, Streptococcus pneumoniae, or group A or B streptococcus, is the important cause.^{11 Keohane EM, et al. Rodak's Hematology. 2025.}

Pregnancy-associated patterns

Gestational thrombocytopenia is the most common cause of thrombocytopenia in pregnancy and is benign once other causes are excluded. Preeclampsia causes thrombocytopenia and can progress to eclampsia, and HELLP syndrome (hemolysis, elevated liver enzymes, low platelets) is a severe variant that is difficult to distinguish from TTP, complement-mediated TMA, HUS, and DIC. ITP remains in the differential at childbearing age, and TTP can recur in pregnancy or postpartum.^{11 Keohane EM, et al. Rodak's Hematology. 2025.}

Nonimmune drug and surface effects

Ristocetin, withdrawn from clinical use, agglutinated platelets through VWF-GPIb binding. Hematin, protamine sulfate, and bleomycin can interact with platelets directly and cause transient thrombocytopenia.^{11 Keohane EM, et al. Rodak's Hematology. 2025.}

The normal spleen sequesters about one third of the platelet mass, so any splenomegaly, including cirrhosis with portal hypertension, lymphoma, sarcoidosis, and chronic myeloid leukemia (CML), can produce mild thrombocytopenia with a normal total body platelet mass. Hypothermia below about 25 °C during cardiovascular surgery causes transient mild thrombocytopenia and a function defect that reverses on rewarming. Extracorporeal circuits damage and partially activate platelets, occasionally producing severe thrombocytopenia with marked functional impairment. Massive transfusion of stored whole blood dilutes and clears platelets, a rarer problem in the component-therapy era. Mild thrombocytopenia also accompanies chronic renal failure, severe iron deficiency, megaloblastic anemia, and chronic hypoxia.^{11 Keohane EM, et al. Rodak's Hematology. 2025.}

Reactive thrombocytosis produces counts of roughly 450 to 800 × 10³/µL, occasionally higher, with normal platelet function. Causes include acute blood loss, splenectomy, childbirth, tissue necrosis and surgery, chronic inflammatory disease, infection, exercise, iron deficiency, hemolytic anemia, renal disorders, and malignancy. Production remains responsive to thrombopoietin, the glycoprotein hormone produced mainly by the liver, and the count normalizes as the underlying disorder resolves. Reactive thrombocytosis has a low complication rate.

Sustained, autonomous thrombocytosis is typical of polycythemia vera (PV), CML, primary myelofibrosis (PMF), and essential thrombocythemia (ET). The count alone cannot establish clonality. Exclude reactive causes first. The physical findings, film, marrow, and genetic workup then establish clonality. The myeloid neoplasia lesson gives the full diagnostic criteria for ET from the fifth-edition WHO classification.^{1212 Tefferi A, et al. Essential thrombocythemia. 2024.}

ET arises from clonal proliferation of a multipotent hematopoietic stem cell and requires a sustained count of at least 450 × 10³/µL. Three mutually exclusive driver mutations account for most cases: JAK2 V617F in about 60%, CALR in about 25%, and MPL in about 3%. About 8% of patients carry none of the three and are called triple-negative. In a series of 1,000 patients, CALR-mutated ET had higher platelet counts with lower rates of arterial and venous thrombosis at or before diagnosis (7% and 4%) than JAK2-mutated disease (16% and 13%).^{1313 Gangat N, et al. One thousand patients with essential thrombocythemia. 2024.} The JAK2 V617F allele burden tends to be higher in PV than in ET, and homozygous clones are more common in PV, but both heterozygous and homozygous patterns occur in either disease. Allele burden alone cannot assign the myeloproliferative neoplasm (MPN) subtype.^{1414 Vannucchi AM, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients… 2007.}

The film can look deceptively benign. Platelets are often normal but can be giant, bizarre, or clumped. Micromegakaryocytes and megakaryocyte fragments appear. Platelets cluster near the thin edge. Anemia is unusual early, and about a third of patients have mild erythrocytosis that must be distinguished from polycythemia vera. Reassess the pattern when marked leukocytosis appears. A platelet count above 400 × 10³/µL with a significant marrow erythropoietic or granulopoietic increase suggests PV or PMF. Dyserythropoiesis or dysgranulopoiesis calls for cytogenetic testing for del(5q), inv(3), or t(3;3).

Laboratory findings correlate with the clinical phenotype. Platelets from patients who have thrombosed show increased fibrinogen-binding affinity, elevated thromboxane B2, and elevated β-thromboglobulin, evidence of ongoing in vivo activation. The hemorrhagic phenotype correlates with qualitative defects such as deficient epinephrine receptors and granule abnormalities. Aggregation results in ET are variable and nonspecific: epinephrine nonresponse alone does not separate ET from reactive thrombocytosis.

Transfusion support in these situations follows blood banking guidance and the institution's transfusion service. The hemostasis lessons describe the procedures behind coagulation testing. In each of these patterns, first confirm the count on the film, then decide how urgently to communicate the result.^{11 Keohane EM, et al. Rodak's Hematology. 2025.}